mardi 25 juillet 2017

Onco Actu du 25 juillet 2017

3.3 Prévention - Vaccins

HPV vaccine: Why aren't children getting it? [CBS News]

3.6 Prévention - Activité physique

Older people should be given dogs on prescription to increase activity [The Telegraph]

4.2 Dép., diag. & prono. - Génome

A DNA App Store Is Here, but Proceed with Caution [MIT Technology Review]

4.7 Dép., diag. & prono. - Col de l'utérus

Cervical smear tests: 'Concerning' delays on results letters [BBC News]

5. Traitements

The Drug Development Paradigm in Oncology: Proceedings of a Workshop (2017) [NAP]

5.10 Traitements - Essais

NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers [NCI]

5.12.2 Immunothérapies - CAR-T

Could CAR-T treatments work in glioblastoma? [FierceBiotech]

Cellectis Granted Patent for CRISPR Use in T-Cells [Cellectis]

Concept paper on the revision of the Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells [EMA]

5.12.3 Immunothérapies-combinaisons

Seattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer [Seattle Genetics]

5.12.4 Immunothérapies - Essais

Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer [Xconomy]

Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Merck]

Merck hit with another late-stage setback on checkpoint star Keytruda [EndPoints]

Merck immunotherapy fails to improve survival in head and neck cancer [Reuters]

5.2 Pharma

Bayer ADC fails pivotal mesothelioma trial [FierceBiotech]

U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Applications for Opdivo (nivolumab) Four-Week Dosing Schedule Across All Approved Indications [BMS]

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin® (bevacizumab) [Pfizer]

5.2.1 Pharma - Partenariats

Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs [Xconomy]

Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as PhII cancer trial looms [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

A new wave of pharma mergers could put innovative drugs in the pipeline [STAT]

5.2.3 Pharma - économie

“The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology” [ProMarket]

5.3 Traitements - FDA, EMA, NICE...

The Expanded Access Navigator – Helping Patients In Need of Potentially Life-Saving Drug Treatments [FDA Voice]

5.3.4 Traitements - AMM (FDA, EMA)

U.S. Food and Drug Administration Expands Approval of Yervoy® (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma [BMS]

5.4 Traitements - Economie

Drug spending in U.S. tops the world. Translation: No pricing-headache relief soon [FiercePharma]

Trump's FDA Commissioner on Drug Prices, Regulations, Science [Bloomberg]

6. Lutte contre les cancers

Leading National Cancer Groups Release Joint Statement to Chart the Future of Cancer Health Disparities Research [ASCO]

6.4 Médico-éco

NHS England takes tough stance on homeopathy [Pharmafile]

'A misuse of scarce funds': NHS to end prescription of homeopathic remedies [The Guardian]

6.7 DMP, Big Data & applis

Google's parent company invested in a hot cancer-testing start-up and built it a dedicated lab [CNBC]

6.7.2 Applis

TNM Classification of Malignant Tumours, 8th Edition [MedHand]

6.9 Controverses

President of troubled French funding agency resigns [Nature]